People · Operator
Named in public records as an officer, director or promoter · active 2007–2018 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Harmony Biosciences II, Inc. | — | Pharmaceuticals | Series D+ | $345.0M | $1.8B | 2018 |
| Inozyme Pharma, Inc. | — | Pharmaceuticals | Series C | $116.2M | $2.4B | 2017 |
| Tarsa Therapeutics, Inc. | — | Biotechnology | Series B | $46.8M | $21.8M | 2010 |
| Logical Therapeutics Inc | — | Biotechnology | Series B | $42.5M | $396.9M | 2007 |
| Stargazer Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $28.5M | $967.8M | 2018 |
Martin Edwards at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Martin Edwards on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Wende Hutton | 1 | 16 |
| Antonio Gracias | 1 | 15 |
| Jack Nielsen | 1 | 13 |
| Edward Mathers | 1 | 12 |
| John Wagner | 1 | 10 |
| Richard Gaster | 1 | 7 |
| Aaron Royston | 1 | 7 |
| Eric Bednarski | 1 | 7 |
| Jeffrey Aronin | 1 | 6 |
| Patrick Morris | 1 | 6 |
| Rob Hopfner | 1 | 6 |
| Axel Bolte | 1 | 6 |
| James Tananbaum | 1 | 6 |
| Lewis Geffen | 1 | 6 |
| Lutz Giebel | 1 | 6 |
| Bryant Fong | 1 | 5 |
| Paul Schmitt | 1 | 5 |
| Ashleigh Palmer | 1 | 4 |
| Richard Levy | 1 | 4 |
| Darien Parhad | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.